Heidelberg ImmunoTherapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Heidelberg ImmunoTherapeutics GmbH
- Target Recruit Count
- 761
- Registration Number
- NCT04539483
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪Infektio Research GmbH & Co. KG, Frankfurt am Main, Germany
🇩🇪Universitätsklinikum Heidelberg - Medizinische Klinik, Klinische Pharmakologie & Pharmakoepidemiologie, Heidelberg, Germany
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Heidelberg ImmunoTherapeutics GmbH
- Target Recruit Count
- 122
- Registration Number
- NCT04165122
- Locations
- 🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪WIR "Walk In Ruhr" im St. Elisabeth Hospital, Bochum, Germany
🇩🇪Praxis Jessen2+Kollegen, Berlin, Germany
© Copyright 2024. All Rights Reserved by MedPath